Skip to content

International GNE Myopathy Patient Registry

International GNE Myopathy Patient Registry (GNE001)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04009226
Enrollment
430
Registered
2019-07-05
Start date
2014-03-01
Completion date
2021-12-01
Last updated
2026-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

GNE Myopathy, Hereditary Inclusion Body Myopathy

Keywords

Distal Myopathies, Neuromuscular Diseases, Muscular Dystrophies, GNE Myopathy, Hereditary Inclusion Body Myopathy

Brief summary

GNE myopathy, an ultra-rare disease, is a severe progressive myopathy that typically presents in early adulthood as weakness in the distal muscles of the lower extremities and progresses proximally, leading to a loss of muscle strength and function, and ultimately a wheelchair-bound state. The rate of progression is gradual and variable over the course of 10-20 years or longer. There is a need to understand the world wide epidemiology of this ultra-rare condition, better understand a long-term disease course and the progression of disease-specific features, support translational research by evaluating burden illness and support clinical research recruitment. Therefore, the study will longitudinally collect information via an online patient registry platform.

Detailed description

GNE myopathy is an ultra- rare condition. Most of the knowledge is coming from case reports or small cohort observations. There is a need to more precisely understand the long-term disease course and the progression of disease-specific features of GNE myopathy, and in turn characterise the overall burden of this illness. Also, to better understand the disease, describe it variability, genotype-phenotype correlation, quality of life, epidemiology, health-economics aspects and need for assistive walking devices. Collected data needs to be harmonised to be compatible collaborative work with Remudy (Japanese patient registry). This collaborative effort will enable the analysis of the largest GNE myopathy data set in the world. To this end, this study will collect patient information longitudinally. Upon patient's agreement, the registry curator can contact nominated clinicians to request additional data or data validation. Study Objectives The objectives of the study are to: * Longitudinally characterize disease-specific features of GNE myopathy * Characterize the burden of illness and quality of life in patients with GNE myopathy * Support recruitment in research activities * Inform registry participants via newsletters about scientific developments in the GNE myopathy field

Interventions

Participants who have volunteered to participate will complete various questionnaires relating to their condition.

Sponsors

Newcastle University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Aged 18 years or older at the time of informed consent * Clinical and/or genetic diagnosis of GNE myopathy (also known as HIBM, QSM, Inclusion Body Myopathy Type 2, DMRV, or Nonaka disease) * Willing and able to provided electronic (or written) consent and comply with all study requirements.

Exclusion criteria

* Under 18 years of age

Design outcomes

Primary

MeasureTime frameDescription
Disease history12 monthsPatient reported disease history including GNE myopathy diagnosis.
General medical history12 monthsPatient reported general medical history.
Medication use12 monthsPatient reported medical use.
Quality of life questionnaire (non-validated)12 monthsPatient reported quality of life
Level of physical activity12 monthsPatient reported level of physical activity
Muscle biopsy and genetic testing status12 monthsPatient reported history of muscle biopsy and details of whether they have undergone genetic testing for GNE myopathy

Countries

United Kingdom

Contacts

PRINCIPAL_INVESTIGATORVolker Straub, MD, PhD

John Walton Muscular Dystrophy Research Centre

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 18, 2026